Navigation Links
Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board

MENLO PARK, Calif., Nov. 27 /PRNewswire/ -- Corium International, Inc., a privately-held transdermal drug delivery company, today announced the appointment of Phyllis Gardner, M.D. and Daniel G. Welch to the Board of Directors. Dr. Gardner, an adjunct partner at Essex Woodlands Health Ventures, is a Professor of Medicine at Stanford University and widely published in the fields of cell biology and pharmacology. In addition to her academic work, Dr. Gardner has been active in the biotechnology and pharmaceutical industries. In 1996, she took a leave of absence from Stanford and joined ALZA Corporation as a Principal Scientist, Vice President of Research, and Head of the ALZA Technology Institute. Dr. Gardner is the co-founder of Genomics Collaborative, Inc. (now a division of Bioserve), SKOLAR MD (acquired by Wolters Klure) and APEX DX, LLC. She currently serves on the boards of Ventaira Pharmaceuticals, UMD, Inc., and Revance, Inc., and she is on the Scientific Advisory Board of Aradigm Corp. Dr. Gardner received her M.D. from Harvard Medical School, and received postgraduate training at Massachusetts General Hospital, Stanford School of Medicine, Columbia University and University College London.

Daniel G. Welch has served as Chief Executive Officer and President of InterMune since September 2003. Prior to InterMune, Mr. Welch was Chairman and CEO of Triangle Pharmaceuticals, a biopharmaceutical company, which was acquired by Gilead. From 2000 to 2002, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for U.S. commercial operations, the international subsidiaries, the R&D function and the diagnostics businesses. Mr. Welch served in several senior management roles at Sanofi-Aventis during the years 1987 to 2000, including Vice President of Worldwide Marketing and COO of the U.S. business. Prior to joining Sanofi-Aventis, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch is a member of the Board of Directors of Seattle Genetics, Inc. and BayBio, the bay-area biotech industry association. He holds an M.B.A. from the University of North Carolina and a B.B.A. from the University of Miami.

Dr. Gardner and Mr. Welch join current Corium board members John Kozarich, Chairman and President, ActivX Biosciences, Inc., Ron Eastman, Chairman of the Board and Partner at Essex Woodlands Health Ventures, Robert Thomas, CEO of Corium and former FoxHollow Technologies CEO, Gary Cleary, co-founder of Corium and CTO, and Ravi Srinivasan, co-founder of Stratagent Life Sciences and VP of Engineering at Corium. The Company recently completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures. Corium is using the proceeds to continue the development and commercialization of a pipeline of advanced transdermal products employing its proprietary MicroCor(TM) microneedle technology, Corplex(TM) polymer adhesive technology, and MicroJet liquid drug delivery technology.

Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.

About Corium International, Inc.

Corium International, Inc. is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development. Please visit

About Essex Woodlands Health Ventures

With $1.6 billion under management, Essex Woodlands is one of the nation's largest and oldest venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, health services, managed care and health information. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography, and brings over 240 years of collective healthcare experience. The team is comprised of 23 professionals with principal offices in Palo Alto, California, Houston, Texas, New York City and London. For more information, please see

Contact: Corium International, Inc.

Christina Dickerson

Director, Corporate Development


SOURCE Corium International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):